logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Lates News

date
21/04/2026
New York spot gold fell below $4810 per ounce, down 0.39% intraday.
Latest
6 m ago
The CEO of Volkswagen has stated that the company may reduce its production capacity by as many as 1 million vehicles.
7 m ago
Crystal Optoelectronics: The development cycle for filter products used in optical communications is relatively short, and it is expected that a small amount of sales contribution will be made within the year.
11 m ago
Inner Mongolia: Strive to cultivate and form three trillion-level industry clusters by the end of the "15th Five-Year Plan".
12 m ago
Recently, the National Medical Products Administration approved the conditional marketing authorization of the innovative drug, Atezolizumab (trade name: Atesinuo), submitted by Bayer HealthCare Pharmaceuticals Inc. through the priority review process. The drug is indicated as a monotherapy for the treatment of unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) in adult patients with HER2 (ERBB2) mutations who have received at least one prior systemic therapy. The marketing of this drug provides patients with a new treatment option. (National Medical Products Administration)
15 m ago
COFCO Group and China National Cereals, Oils and Foodstuffs Corporation sign a strategic cooperation framework agreement.
See all latestmore
logo
Contact US
qr
+852 - 60190728
[email protected]
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.